Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Shah Discusses P53-Mutated Mantle Cell Lymphoma

October 24th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Rituximab Maintenance After ASCT Prolongs Survival in MCL

October 19th 2017

Maintenance rituximab (Rituxan) following autologous stem-cell transplantation improved survival in younger patients with mantle cell lymphoma, according to the LyMa trial.

Dr. Epperla Discusses the Current Treatment of MCL

October 18th 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma.

Dr. Shah Discusses Autologous Transplant in MCL

October 18th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Expert Covers Burgeoning Advancements in Follicular Lymphoma and MCL

October 18th 2017

Narendranath Epperla, MD, discusses the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Dr. Eskelund on Outcomes of TP53-Mutated MCL

October 11th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

TP53 Predicts Poorer Survival in Mantle Cell Lymphoma

October 9th 2017

Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53 mutations predicted worse overall survival in younger patients with mantle cell lymphoma.

Observation After Diagnosis Viable Strategy for Some Patients With MCL

September 21st 2017

Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.

Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL

September 19th 2017

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.

Ibrutinib Highly Active Against MCL in Pooled Analysis

September 19th 2017

In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.

Dr. Hamlin on Future Combination Strategies in the MCL Landscape

September 6th 2017

Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

Dr. Martin on Potential for CAR T-Cell Therapy in MCL Landscape

September 1st 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).

Dr. Nowakowski on Using Patient Performance Score and Age for MCL Treatment

August 28th 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the use of patient performance status and age to make treatment decisions for patients with mantle cell lymphoma (MCL).

Dr. Shah on Excitement With Venetoclax in Patients With MCL

August 22nd 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the potential with venetoclax (Venclexta) in patients with mantle cell lymphoma (MCL).

Dr. Hamlin on Next Steps With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

August 21st 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Martin on Potential of Immunotherapy in MCL Landscape

August 18th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Dr. Nowakowski on Biological Heterogeneity in Newly Diagnosed Patients With MCL

August 16th 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the desire to use biological heterogeneity as a factor for treatment in newly diagnosed patients with mantle cell lymphoma (MCL).

Dr. Ansell on Difficult Challenges in the MCL Landscape

August 15th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).

Dr. Shah on Options for Ibrutinib-Intolerant Patients With MCL

August 11th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Higher Bortezomib Doses Linked to Longer OS in MCL

August 10th 2017

Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).